The recent FLASH2 study investigated the safety and efficacy of treatment of moderate to severe uncontrolled asthma in adults. Find out how uMed's end-to-end approach to patient identification, engagement, and screening enabled delivery of 3.5x the initial recruitment target of 33 referrals, mobilising a highly-qualified patient population across 14 trial sites.
.png)
FLASH2 investigated the safety and efficacy of Atuliflapon, a novel investigational medication for the treatment of moderate to severe uncontrolled asthma in adults. The study sought male and female adults participants aged 18–80, with an asthma diagnosis confirmed at least 12 months prior to screening. With an initial target of 33 highly-qualified patient referrals, uMed engaged over 70k patients across 14 study sites through its clinically-validated 'Recruit' EHR identification and screening process, ultimately referring 115 to trial.
